Free Newsletter
Institutions lament squeeze on federal research funds
Research institutions are lining up to protest stalled federal funding for biomedical research. Dr. Edward D. Miller, the head of Johns Hopkins Medical, issued a stern warning to lawmakers that a failure to bump federal research funding at the National Institutes of Health could force a frustrating halt to important research. "The world's premier biomedical research engine is at risk," he said in a statement. A stagnant source of funds has left eight out of 10 research grant applications without funds, says Dr. Miller, while the National Cancer Institute says it can only fund about one in 10 applications. Johns Hopkins has a lot to lose in the current funding environment. The university's researchers traditionally garner more federal funds than any other institution in the country. Last year that amounted to $1.28 billion in federal funds. The university joined a lineup of institutions which produced "Within Our Grasp--Or Slipping Away? Assuring a New Era of Scientific and Medical Progress." The report outlines the advances made possible when NIH funding was doubled between 1998 and 2003.
- read the report from the Baltimore Business Journal
ALSO: There's a lot at stake for states like Florida, which has invested more than $850 million in a trio of new research institutions. Editorial
Related Articles:
NIH budget cuts cause alarm in research circles. Report
NIH expert sees new drive against rare disease. Report
NIH chief breaks with Bush on stem cell research. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: